Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target? by Ilaria Saltarella, Maria Antonia Frassanito, Aurelia Lamanuzzi, Arianna Brevi, Patrizia Leone, Vanessa Desantis, Lucia Di Marzo, Matteo Bellone, Daniele Derudas, Domenico Ribatti, Raffaella Chiaramonte, Maria Teresa Palano, Antonino Neri, Maria Addolorata Mariggiò, Ruggiero Fumarulo, Franco Dammacco, Vito Racanelli, Angelo Vacca, Roberto Ria

“…MMECs showed higher expression of Jagged1/2 ligands, of activated Notch1/2 receptors, and of Hes1/Hey1 Notch target genes than ECs from monoclonal gammopathy of undetermined significance patients, suggesting that homotypic activation of Notch pathway occurs in MM. …”
Get full text

Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones by Libere J. Ndacayisaba, Kate E. Rappard, Stephanie N. Shishido, Carmen Ruiz Velasco, Nicholas Matsumoto, Rafael Navarez, Guilin Tang, Pei Lin, Sonia M. Setayesh, Amin Naghdloo, Ching-Ju Hsu, Carlisle Maney, David Symer, Kelly Bethel, Kevin Kelly, Akil Merchant, Robert Orlowski, James Hicks, Jeremy Mason, Elisabeth E. Manasanch, Peter Kuhn

“…In this study, we applied an enrichment-free four-plex (CD138, CD56, CD45, DAPI) immunofluorescence assay and single-cell DNA sequencing for morphogenomic characterization of plasma cells to detect and delineate common and rare plasma cells and discriminate between normal and malignant plasma cells in paired blood and bone marrow aspirates from five patients with newly diagnosed myeloma (<i>N</i> = 4) and monoclonal gammopathy of undetermined significance (n = 1). Morphological analysis confirms CD138+CD56+ cells in the peripheral blood carry genomic alterations that are clonally identical to those in the bone marrow. …”
Get full text

The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches by Ivana Lagreca, Giovanni Riva, Vincenzo Nasillo, Patrizia Barozzi, Ilaria Castelli, Sabrina Basso, Francesca Bettelli, Davide Giusti, Angela Cuoghi, Paola Bresciani, Andrea Messerotti, Andrea Gilioli, Valeria Pioli, Corrado Colasante, Daniela Vallerini, Ambra Paolini, Monica Maccaferri, Francesca Donatelli, Fabio Forghieri, Monica Morselli, Elisabetta Colaci, Giovanna Leonardi, Roberto Marasca, Leonardo Potenza, Rossella Manfredini, Enrico Tagliafico, Tommaso Trenti, Patrizia Comoli, Mario Luppi

“…Multiple Myeloma (MM) is a malignant growth of clonal plasma cells, typically arising from asymptomatic precursor conditions, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). …”
Get full text

Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies by Ivana Lagreca, Vincenzo Nasillo, Patrizia Barozzi, Ilaria Castelli, Sabrina Basso, Sara Castellano, Ambra Paolini, Monica Maccaferri, Elisabetta Colaci, Daniela Vallerini, Patrizia Natali, Daria Debbia, Tommaso Pirotti, Anna Maria Ottomano, Rossana Maffei, Francesca Bettelli, Davide Giusti, Andrea Messerotti, Andrea Gilioli, Valeria Pioli, Giovanna Leonardi, Fabio Forghieri, Paola Bresciani, Angela Cuoghi, Monica Morselli, Rossella Manfredini, Giuseppe Longo, Anna Candoni, Roberto Marasca, Leonardo Potenza, Enrico Tagliafico, Tommaso Trenti, Patrizia Comoli, Mario Luppi, Giovanni Riva

“…Multiple Myeloma (MM) typically originates from underlying precursor conditions, known as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM). …”
Get full text

Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma by Aina Oliver-Caldes, Aina Oliver-Caldes, Juan Carlos Soler-Perromat, Ester Lozano, Ester Lozano, David Moreno, David Moreno, Alex Bataller, Alex Bataller, Pablo Mozas, Pablo Mozas, Marta Garrote, Xavier Setoain, Juan Ignacio Aróstegui, Jordi Yagüe, Natalia Tovar, Natalia Tovar, Raquel Jiménez, Raquel Jiménez, Luis Gerardo Rodríguez-Lobato, Luis Gerardo Rodríguez-Lobato, M. Teresa Cibeira, M. Teresa Cibeira, Laura Rosiñol, Laura Rosiñol, Joan Bladé, Joan Bladé, Manel Juan, Manel Juan, Carlos Fernández de Larrea, Carlos Fernández de Larrea

“…A detectable M-protein with a monoclonal gammopathy of undetermined significance (MGUS)-like behavior was detected in one-third of LTR after ASCT. …”
Get full text

Monoclonal Gammopathy of Renal Significance—A Rare Renal Presentation: A Review of Cases Reported by Asim Kichloo MD, Najma Nawaz MD, Jagmeet Singh MD, Michael Aljadah MD, Michael Stanley Albosta MD, Ravinder Bhanot MD

“…Monoclonal gammopathy of undetermined significance is a precursor to multiple myeloma characterized by monoclonal gammopathy without evidence of end organ damage. …”
Get full text

Monoclonal Gammapathy of Renal Significance: Morphological Variants of Lesion by N. V. Fomina, E. V. Utkina

“…This nosological group was identified within the group of monoclonal gammopathies of undetermined significance (in 2012). The data on the study of morphological kidney damage associated with monoclonal renal gammopathy are presented. …”
Get full text

Epidemiology of monoclonal gammopathy in Morocco – A hospital‐based study by Zohra Ouzzif, Kamal Doghmi, Nezha Messaoudi, Sanae Bouhsain, Samira El Machtani, Asmae Biaz, Achraf Rachid, Abdallah Dami, Ahmed Bezza, Aissam El Maataoui

“…Plasma cell proliferative disorders in our study were as follows, multiple myeloma (MM) (45.65%), Monoclonal gammopathies of undetermined significance (MGUS) (39.05%), Waldenstrom's macroglobulinemia (5.58%), Lymphoma (2.27% + 1.2%), Chronic Lymphocytic Leukemia (2.48%), Plasma cell leukemia (1.86%), Plasmacytoma (0.62%), POEMS syndrome (0.41%), and Amyloidosis (0.84%). …”
Get full text

REAL-LIFE STUDY OF BIO-CLINICAL FOLLOW-UP AFTER BNT162b2 mRNA COVID-19 (BNTCV) VACCINATION IN 235 PATIENTS (PTS) INCLUDING 225 WITH HEMATOLOGICAL MALIGNANCIES (HM). by Jean-François Rossi, Emmanuel Bonnet, Marion Velensek, Emma Wisniewski, Sophie Heraud, Rania Boustany, Céleste David, Jérôme Dinet, Roland Sicard, Jean-Pierre Daures, Marion Bonifacy, Lysiane Mousset, Christel Castelli, Emmanuel Goffart

“…In this real-life study, 235 pts vaccinated with BNTCV (BioNTech Pfizer) were monitored for 2 years, starting 06/20 in a single Institution.Patients ’population and follow-up. 235 patients including 225 with HM initially received 2 doses of BNTCV (IM) with 3 weeks between the 2 first doses, including 98 lymphomas (L), 28 monoclonal gammopathies with undetermined significance (MGUS), 34 multiple myelomas (MM), 34 myeloproliferative disorders (MPD), 27 chronic lymphocytic leukemias (CLL), 4 acute leukemias and 10 non-malignant hemopathies. …”
Get full text